New genomic testing solution designed to shorten diagnostic journeys for patients and families;
supports efforts to reduce the economic and societal burden of rare diseases in the U.S.A.
Natera, Inc., a global leader in cell-free DNA testing and precision medicine, has announced the commercial launch of Zenith Genomics, a next-generation whole genome sequencing assay designed to significantly improve the detection and diagnosis of rare genetic diseases. The new platform was introduced at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Baltimore, Maryland, where Natera is presenting insights into the technology’s clinical capabilities and performance.
Zenith Genomics was developed to address one of the most persistent challenges in modern healthcare: accurate and timely diagnosis of rare genetic disorders. Rare diseases affect an estimated 30 million Americans, yet many patients experience prolonged diagnostic journeys that can take four to seven years on average. These delays often lead to extended medical testing, increased healthcare costs, and emotional strain for patients and families. The economic impact of rare diseases in the United States was estimated at $997 billion in 2019, highlighting the urgent need for more advanced diagnostic solutions.
Health Technology Insights: https://healthtechnologyinsights.com/genomic-ai-how-artificial-intelligence-is-powering-dna-based-nutrition-and-therapy/
Built on a comprehensive whole-genome sequencing backbone, Zenith Genomics uses advanced sequencing technology combined with enhanced interpretation capabilities to identify genetic variants that are traditionally difficult to detect. The platform improves detection of complex genomic features such as tandem repeat expansions, using long-read sequencing confirmation to provide deeper diagnostic clarity. This approach allows clinicians to identify a wide spectrum of rare and ultra-rare conditions while supporting targeted treatment strategies and long-term patient management.
The technology behind Zenith Genomics was developed through a collaboration with MyOme, a clinical whole genome analysis company focused on helping families better understand genetic disease risk. Through this partnership, Natera will bring the assay to healthcare providers across the United States, leveraging its established infrastructure that includes electronic medical record (EMR) integrations, clinical support services, and expertise in high-complexity genomic testing.
Meredith Reichert, Ph.D., Senior Vice President of Commercial and General Manager of Rare Disease at Natera, emphasized the impact the new platform could have on patients and healthcare systems. She noted that families affected by rare diseases often endure lengthy diagnostic processes that delay treatment and increase financial burden. By combining MyOme’s genomic innovation with Natera’s nationwide clinical reach, Zenith Genomics has the potential to deliver clearer answers to more patients earlier in their healthcare journey.
Akash Kumar, M.D., Ph.D., Chief Medical Officer at MyOme, highlighted the broader mission behind the technology. He explained that unlocking the full potential of the human genome can significantly improve health outcomes, and the partnership with Natera enables the rapid and responsible scaling of advanced genomic diagnostics to reach more patients in need.
As genomic sequencing continues to gain recognition as a standard of care for rare disease evaluation, Zenith Genomics is positioned for strong adoption across healthcare systems. Expanding reimbursement support from both public and private payers further reflects the growing clinical value of comprehensive genomic testing.
At the ACMG meeting, Natera is presenting real-world insights demonstrating how Zenith Genomics can enhance diagnostic accuracy across diverse patient populations. With its combination of advanced sequencing, clinical integration, and precision medicine capabilities, the platform represents an important step forward in improving rare disease detection and guiding personalized healthcare strategies.
Health Technology Insights: https://healthtechnologyinsights.com/the-new-era-of-gene-editing-what-crispr-means-for-patients/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
